• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体细胞 RIT1 缺失在动静脉畸形中过度激活 RAS-MAPK 信号通路,可被 MEK 抑制。

Somatic RIT1 delins in arteriovenous malformations hyperactivate RAS-MAPK signaling amenable to MEK inhibition.

机构信息

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, VASCERN VASCA European Reference Centre, 79106, Freiburg, Germany.

Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany.

出版信息

Angiogenesis. 2024 Nov;27(4):739-752. doi: 10.1007/s10456-024-09934-8. Epub 2024 Jul 5.

DOI:10.1007/s10456-024-09934-8
PMID:38969873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11564399/
Abstract

Arteriovenous malformations (AVM) are benign vascular anomalies prone to pain, bleeding, and progressive growth. AVM are mainly caused by mosaic pathogenic variants of the RAS-MAPK pathway. However, a causative variant is not identified in all patients. Using ultra-deep sequencing, we identified novel somatic RIT1 delins variants in lesional tissue of three AVM patients. RIT1 encodes a RAS-like protein that can modulate RAS-MAPK signaling. We expressed RIT1 variants in HEK293T cells, which led to a strong increase in ERK1/2 phosphorylation. Endothelial-specific mosaic overexpression of RIT1 delins in zebrafish embryos induced AVM formation, highlighting their functional importance in vascular development. Both ERK1/2 hyperactivation in vitro and AVM formation in vivo could be suppressed by pharmacological MEK inhibition. Treatment with the MEK inhibitor trametinib led to a significant decrease in bleeding episodes and AVM size in one patient. Our findings implicate RIT1 in AVM formation and provide a rationale for clinical trials with targeted treatments.

摘要

动静脉畸形(AVM)是一种易引起疼痛、出血和进行性生长的良性血管异常。AVM 主要由 RAS-MAPK 通路的镶嵌致病性变异引起。然而,并非所有患者都能确定致病变异。通过超深度测序,我们在 3 名 AVM 患者的病变组织中发现了新型体细胞 RIT1 delins 变异。RIT1 编码一种可以调节 RAS-MAPK 信号的 RAS 样蛋白。我们在 HEK293T 细胞中表达 RIT1 变异体,导致 ERK1/2 磷酸化显著增加。斑马鱼胚胎内皮特异性镶嵌过表达 RIT1 delins 可诱导 AVM 形成,突出了其在血管发育中的功能重要性。体外 ERK1/2 过度激活和体内 AVM 形成均可被 MEK 抑制的药理学抑制所抑制。MEK 抑制剂 trametinib 的治疗导致一名患者出血发作和 AVM 大小显著减少。我们的研究结果表明 RIT1 参与了 AVM 的形成,并为靶向治疗的临床试验提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/c21c8dde7e01/10456_2024_9934_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/41191f3a5f6a/10456_2024_9934_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/dbe591502363/10456_2024_9934_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/24394a89fae2/10456_2024_9934_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/3594ea3a2c48/10456_2024_9934_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/c21c8dde7e01/10456_2024_9934_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/41191f3a5f6a/10456_2024_9934_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/dbe591502363/10456_2024_9934_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/24394a89fae2/10456_2024_9934_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/3594ea3a2c48/10456_2024_9934_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d21/11564399/c21c8dde7e01/10456_2024_9934_Fig5_HTML.jpg

相似文献

1
Somatic RIT1 delins in arteriovenous malformations hyperactivate RAS-MAPK signaling amenable to MEK inhibition.体细胞 RIT1 缺失在动静脉畸形中过度激活 RAS-MAPK 信号通路,可被 MEK 抑制。
Angiogenesis. 2024 Nov;27(4):739-752. doi: 10.1007/s10456-024-09934-8. Epub 2024 Jul 5.
2
Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway.血管内皮 MAP2K1 突变导致动静脉畸形激活 RAS/MAPK 通路。
Biochem Biophys Res Commun. 2020 Aug 20;529(2):450-454. doi: 10.1016/j.bbrc.2020.06.022. Epub 2020 Jul 1.
3
Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor.RIT1 过表达激活 RAS/MAPK 信号通路,并增强肝癌对索拉非尼和 AKT 抑制剂联合治疗的敏感性。
Oncogene. 2022 Jan;41(5):732-744. doi: 10.1038/s41388-021-02130-8. Epub 2021 Nov 29.
4
Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy.镶嵌性 RAS/MAPK 变异导致散发性血管畸形,对靶向治疗有反应。
J Clin Invest. 2018 Apr 2;128(4):1496-1508. doi: 10.1172/JCI98589. Epub 2018 Mar 12.
5
Mutations in RIT1 cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype.RIT1基因的突变导致努南综合征——更多功能证据及临床表型扩展
Clin Genet. 2016 Mar;89(3):359-66. doi: 10.1111/cge.12608. Epub 2015 Jun 4.
6
Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy.监测动静脉畸形对基因靶向治疗的反应。
Pediatrics. 2020 Sep;146(3). doi: 10.1542/peds.2019-3206.
7
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.MEK 抑制剂曲美替尼不能阻止间变性淋巴瘤激酶(ALK)依赖性神经母细胞瘤的生长。
Sci Signal. 2017 Nov 28;10(507):eaam7550. doi: 10.1126/scisignal.aam7550.
8
Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise.成功应用曲美替尼治疗毛细血管畸形-动静脉畸形综合征伴心脏合并症患者的动静脉畸形
Pediatr Dermatol. 2022 Mar;39(2):316-319. doi: 10.1111/pde.14912. Epub 2022 Jan 10.
9
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.RIT1 中的功能获得性突变导致努南综合征,一种 RAS/MAPK 通路综合征。
Am J Hum Genet. 2013 Jul 11;93(1):173-80. doi: 10.1016/j.ajhg.2013.05.021. Epub 2013 Jun 20.
10
Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.核糖体蛋白 S6 磷酸化的早期反应与结直肠癌细胞对曲美替尼的敏感性相关。
Lab Invest. 2021 Aug;101(8):1036-1047. doi: 10.1038/s41374-021-00590-w. Epub 2021 Apr 28.

引用本文的文献

1
NSC-derived extracellular vesicles-mediates neuronal plasticity enhancement in vascular dementia via transferring miR-210.源自神经干细胞的细胞外囊泡通过转运miR-210介导血管性痴呆中神经元可塑性的增强。
Acta Neuropathol Commun. 2025 Jul 9;13(1):152. doi: 10.1186/s40478-025-02073-1.
2
Diagnosis and management of superficial arteriovenous malformations: French healthcare network's recommendations.浅表动静脉畸形的诊断与管理:法国医疗保健网络的建议。
Orphanet J Rare Dis. 2025 Jan 30;20(1):45. doi: 10.1186/s13023-024-03413-5.

本文引用的文献

1
Intimal Injury Potentially Plays a Key Role in the Formation of Carotid Artery Dissection: A Novel Animal Model Establishing.内皮下损伤可能在颈动脉夹层形成中起关键作用:一种新的动物模型建立。
Cerebrovasc Dis. 2024;53(2):224-232. doi: 10.1159/000531657. Epub 2023 Jul 3.
2
Case report study of thalidomide therapy in 18 patients with severe arteriovenous malformations.18例严重动静脉畸形患者使用沙利度胺治疗的病例报告研究
Nat Cardiovasc Res. 2022 Jun;1(6):562-567. doi: 10.1038/s44161-022-00080-2. Epub 2022 Jun 10.
3
Extracranial Vascular Anomalies Driven by RAS/MAPK Variants: Spectrum and Genotype-Phenotype Correlations.
RAS/MAPK 变异驱动的颅外血管异常:谱及基因型-表型相关性。
J Am Heart Assoc. 2024 Apr 16;13(8):e033287. doi: 10.1161/JAHA.123.033287. Epub 2024 Apr 2.
4
Advances in the Study of KRAS in Brain Arteriovenous Malformation.脑动静脉畸形中KRAS的研究进展
Cerebrovasc Dis. 2024;53(6):767-775. doi: 10.1159/000535139. Epub 2023 Nov 10.
5
rasa1-related arteriovenous malformation is driven by aberrant venous signalling.与RASA1相关的动静脉畸形由异常的静脉信号传导驱动。
Development. 2023 Sep 15;150(18). doi: 10.1242/dev.201820. Epub 2023 Sep 14.
6
Case Report: Progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition.病例报告:RAS 病中的进行性中央传导性淋巴异常。两例病例报告,包括通过 MEK 抑制进行的成功治疗。
Front Genet. 2022 Sep 27;13:1001105. doi: 10.3389/fgene.2022.1001105. eCollection 2022.
7
mTOR-FABP4 signal is activated in brain arteriovenous malformations in humans.mTOR-FABP4 信号在人脑动静脉畸形中被激活。
J Mol Med (Berl). 2022 Sep;100(9):1287-1297. doi: 10.1007/s00109-022-02237-9. Epub 2022 Jul 25.
8
Molecular pathways and possible therapies for head and neck vascular anomalies.头颈部血管异常的分子途径和可能的治疗方法。
J Oral Pathol Med. 2022 Nov;51(10):878-887. doi: 10.1111/jop.13318. Epub 2022 Jul 4.
9
Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations.颅内动静脉畸形的体细胞突变景观与表型相关性。
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):905-912. doi: 10.1111/jdv.18046. Epub 2022 Mar 11.
10
Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise.成功应用曲美替尼治疗毛细血管畸形-动静脉畸形综合征伴心脏合并症患者的动静脉畸形
Pediatr Dermatol. 2022 Mar;39(2):316-319. doi: 10.1111/pde.14912. Epub 2022 Jan 10.